We are required to switch to intradermal per our health department who supplies the vaccine to us but may of course still give it subQ for persons <18 years old or with history of keloid scars. The
original study showed increased rates of erythema and induration, which matches with Peter's comment. If it were up to me, I would probably do the split method of giving subQ for immunocompetent folks and ID for immunocompromised persons. However, if you don't think you will be getting more than 80 vials anytime soon, then I think doing 100% ID is reasonable in order to maximize number of persons who can get vaccinated overall.
------------------------------
Caitlin Prather, PharmD, BCACP, AAHIVP, TTS
Clinical Pharmacist in Fairfax, VA
------------------------------
Original Message:
Sent: 08-23-2022 14:17
From: Brian Hilgeman
Subject: strategy for MPX vaccination
Hi all - We just received an allotment of JYNNEOS vaccine for our RW population. We received 80 vials but have a population of 250 plwh.
What is your current strategy for vaccination - intradermal for all, subcutaneous for all, intradermal if CD4 > 350/subcu for those < 350. Thoughts?
Brian
Sixteenth Street CHC
Medical Director of HIV
------------------------------
Brian Hilgeman
Sixteenth Street Community Health Centers
Muskego WI
------------------------------